Phenotypic and Genotypic Characterization of Multi-Drug Resistant Mycobacterium tuberculosis
DOI:
https://doi.org/10.47430/ujmr.2051.004Keywords:
Multi-drug resistance,, M. tuberculosis,, phenotypic,, genotypic, LJ-proportion,, Geno Type MTBDRplus, LPA,, RIF,, INHAbstract
This study characterized multi-drug resistant M. tuberculosis phenotypically by LJ-proportion method and genotypically by Geno Type MTBDR plus LPA. Out of the forty M. tuberculosis isolates tested, two (5.0%) were found to be multi-drug resistant by LJ proportion method and one (2.5%) was MDR by LPA. None was found to be mono-resistant to any of the drugs by LJ however, one isolate was mono resistant to RIF and one was mono resistant to INH by LPA. Comparison of Geno Type MTBDRplus LPA and phenotypic LJ-proportion methods showed that one isolate was mono resistant to RIF and one was mono resistant to INH by LPA, one and two MDR-TB isolates respectively were characterized by genotypic and phenotypic methods. The remaining isolates were found to be pan susceptible by both methods. One isolate was characterized as MDR with bands at rpoβ MUT2A region and ihnA MUT2 corresponding to H526Y and A16G mutations respectively. Rifampicin mono resistance with band at rpoβ MUT3 corresponding to S531L was found in one isolate. Also, isoniazid mono resistance was observed in one isolate with ihnA MUT2 band corresponding to A16G mutation. This study has shown an overall high prevalence of MDR-TB in the study area which needs to be urgently addressed. Laboratory facilities for rapid drug resistance detection are needed across the country for early and accurate diagnosis of TB and drug resistant cases. This remains an important step in managing TB drug resistance in Nigeria.
Downloads
References
Ando, H., Miyoshi-Akiyama. T., Watanabe, S. and Kirikae, T. (2014). A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis. Molecular Microbiology, 91(3):538-547.
https://doi.org/10.1111/mmi.12476
Balasubramanian, S., Gayathri, R., Madhavan, H.N., Natrajan, S. and Lily Therese, K. (2012). Phenotypic and genotypic characteristics of drug resistance in Mycobacterium tuberculosis isolates from pediatric population of Chennai, India. Indian Journal of Medical Microbiology, 30(4):411-417
https://doi.org/10.4103/0255-0857.103761
Canetti, G., Froman, S., Grosset, J., Hauduroy, P., Langerova, M., Mahler, H.T., Meissner, G., Mitchison, D.A., and Sula,L. (1963). Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. Bulletin of the World Health Organization, 29:565-578.
Canetti, G., Fox, W., Khomenko, A., Mahler, H.T., Menon, N.K., Mitchison, D.A.,Rist, N., Smelev, N.A. (1969). Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control program. Bulletin of World Health Organization, 41(1):21-43.
Cohen, T., Sommers, B. and Murray, M. (2003). The effect of drug resistance on the fitness ofMycobacterium tuberculosis. Lancet, 3:13-21 29
https://doi.org/10.1016/S1473-3099(03)00483-3
Cohn, D.L., Flavia, B. And Raviglione, M.C. (1997). Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clinical Infectious Diseases, 24:S121-30.
https://doi.org/10.1093/clinids/24.Supplement_1.S121
Comas, I., Borrell, S., Roetzer, A., Rose, G., Malla, B., Kato-Maeda, M., Galagan J, Niemann S, and Gagneux, S. (2011). Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nature Genetics, 44(1):106-110.
https://doi.org/10.1038/ng.1038
De Beenhouwer, H., Lhiang, Z., Jannes, G., Mijs, W., Machtelinckx, L., Rossau, R., Traore, H., and Portaels, F. (1995) Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuberculosis and Lung Diseases, 76(5):425-430.
https://doi.org/10.1016/0962-8479(95)90009-8
Dye, C., Williams, B.G., Espinal, M.A., and Raviglione, M.C. (2002)."Erasing the world's slow stain: strategies to beat multi drug resistant tuberculosis,"Science, 295(5562): 2042-2046.
https://doi.org/10.1126/science.1063814
Espinal, M. A., Laszlo, A. and Simonsen, L. (2001). Global trends in the resistance to antituberculosis drugs. New England Journal of Medicine, 344:1294-1303.
https://doi.org/10.1056/NEJM200104263441706
Foundation for innovative new diagnosis (FIND) (2012). Molecular Detection of Drug- Resistant Tuberculosis by Line Probe Assay; Laboratory Manual for Resource- Limited Settings.www.finddiagnostics.org.
Gumbo, T. (2010). New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and PopulationPharmacokinetic Variability. Antimicrobial Agents andChemotherapy, 54 (4):1484-1491.
https://doi.org/10.1128/AAC.01474-09
Hillemann, D., Weizenegger, M., Kubica, T., Richter, E., and Niemann, S. (2005). Use of the Geno Type MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. Journal of Clinical Microbiology,43 (8):3699- 3703.
https://doi.org/10.1128/JCM.43.8.3699-3703.2005
Hillemann, D., Rusch-Gerdes, S., and Richter,E. (2007). Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. Journal of Clinical Microbiology, 45 (8):2635-2640.
https://doi.org/10.1128/JCM.00521-07
Iseman, M. D. (1993). Treatment of multidrug resistant tuberculosis. NewEngland Journal of Medicine; 329: 784-791
https://doi.org/10.1056/NEJM199309093291108
Jamieson, F.B., Guthrie, J.L., Neemuchwala, A., Lastovetska, O., Melano, R.G., and Mehaffy, C.(2014). Profiling of rpoβ mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. Journal of Clinical Microbiology, 52 (6):2157-2162.
https://doi.org/10.1128/JCM.00691-14
Ling, D.I., Zwerling, A.A., and Pai, M. (2008). GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. European Respiratory Journal, 32(5):1165-1174. Mycobacterium tuberculosis. Lancet, 3:13-21
https://doi.org/10.1183/09031936.00061808
Rieder, H.L. (1999). Epidemiologic basis of tuberculosis control. 1st edition: International Union Against Tuberculosis and Lung Disease, Paris. Pp. 162.
Rossau, R., Traore, H., De Beenhouwer, H., Mijs, W., Jannes, G., De Rijk, P. and Portaels, F. (1997). Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrobial Agents and Chemotherapy, 41(10):2093-2098.
https://doi.org/10.1177/0193841X9702100305
Somoskovi, A., Parsons, M. L. and Salfinger, M. (2001):The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respiratory Research 2(3). 164-169
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 UMYU Journal of Microbiology Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
